bc3402
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 18, 2023 (NCT05970822)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
inhibitor - TIM3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06608940 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Case Western Reserve University |
| NCT06111326 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Biocity Biopharmaceutics Co., Ltd., Fudan University |
| NCT05690425 | Phase 1 | Jul 6, 2023 | Biocity Biopharmaceutics Co., Ltd., Jinan University |
| NCT05970822 | Phase 1 | Jun 18, 2023 | Biocity Biopharmaceutics Co., Ltd., Chinese Academy of Medical Sciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocity Biopharmaceutics Co., Ltd. | For profit | 3 | 3 | 2 | 2023 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Jinan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1